logo
logo
HAE stock ticker logo

Haemonetics Corporation

NYSE•HAE
CEO: Mr. Christopher A. Simon
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1991-05-10
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Contact Information
125 Summer Street, Boston, MA, 02110, United States
781-848-7100
www.haemonetics.com
Market Cap
$2.80B
P/E (TTM)
16.0
34.5
Dividend Yield
--
52W High
$87.32
52W Low
$47.32
52W Range
32%
Rank21Top 7.6%
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2026 Data

Revenue

$338.97M+0.00%
4-Quarter Trend

EPS

$0.96+0.00%
4-Quarter Trend

FCF

$87.22M+0.00%
4-Quarter Trend

2026 Q3 Earnings Highlights

Key Highlights

Operating Income Strong Growth Operating Income reached $179.8M for nine months, showing strong 19.5% reported growth driven by pricing and lower restructuring.
Net Income Improvement Net Income grew 7.1% to $117.5M for nine months, benefiting from margin expansion and cost control efforts.
Gross Margin Expansion Gross Margin expanded to 59.7% (9M), a 5.7 point increase driven by continued product portfolio transformation efforts.
Operating Cash Flow Surge Operating Cash Flow surged to $222.3M (9M), significantly higher than $65.2M provided in the prior year nine months period.

Risk Factors

Top Line Revenue Decline Net Revenues declined 4.1% to $987.7M (9M), impacted by Whole Blood divestiture and major customer transition.
Intangible Asset Impairment Intangible asset impairment charge reached $9.3M (9M), a 289.0% increase year-over-year related to HemoAssay IP.
Near-Term Debt Maturity Significant debt maturity risk as $300.0M principal balance of 2026 Notes is scheduled to mature March 1, 2026.
Foreign Exchange Volatility High foreign exchange exposure exists; international sales comprised 26.1% of total revenue for the nine months ended period.

Outlook

Vivasure Medical Acquisition Acquired Vivasure Medical for $116.4M upfront cash, expanding Hospital unit portfolio in interventional cardiology market.
Share Repurchase Program Active New $500.0M share repurchase program approved through April 2028; $425.0M remains authorized as of December 27.
Restructuring Costs Decreasing Restructuring costs significantly decreased to $3.1M (3M period) as prior portfolio rationalization initiatives are now closed.
Revenue Backlog Visibility $36.6M of remaining performance obligations expected to be recognized as revenue within the next twelve months.

Peer Comparison

Revenue (TTM)

BHC stock ticker logoBHC
$10.31B
+7.1%
XRAY stock ticker logoXRAY
$3.68B
-3.0%
ACHC stock ticker logoACHC
$3.31B
+5.0%

Gross Margin (Latest Quarter)

AGIO stock ticker logoAGIO
96.9%
-4.3pp
BEAM stock ticker logoBEAM
95.0%
-471.3pp
CPRX stock ticker logoCPRX
90.8%
-2.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
WRBY$2.95B1806.20.5%32.3%
ITGR$2.91B28.16.0%41.0%
CON$2.88B17.046.6%69.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.8%
Moderate Growth
4Q Net Income CAGR
-8.3%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:May 6, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data